P6. Abstract Title: Risks and Benefits of Antithrombotic Therapy in Polycythemia Vera: A Systematic Review

Thrombosis is the major cause of morbidity and mortality in patients with polycythemia vera (PV). Aspirin, and phlebotomy with or without cytoreductive therapy are key components of PV management to reduce thrombotic risk. However, patients with PV are also at risk for hemorrhagic complications, especially in the context of thrombocytosis and acquired Von Willebrand factor deficiency. The net benefit of antithrombotic therapy for primary and secondary thromboprophylaxis is uncertain. A systematic review conducted in 2013 identified 2 randomized control trials (RCTs) and concluded that low-dose aspirin does not increase the risk of major bleeding and is associated with a clinically but not statistically significant reduction in fatal thrombotic events.

Source: Thrombosis Research - September 30, 2019 Category: Hematology Authors: M. Laureano, L. Goodlife, D. Chu, D. Siegal Source Type: research